Elena Levtchenko

List of Publications by Year
in descending order

201	6,759	61984	88630
papers	citations	43 h-index	70 g-index

211	211	211	7396
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nature Reviews Nephrology, 2019, 15, 435-455.	9.6	318
2	Connective tissue growth factor (CTGF) from basics to clinics. Matrix Biology, 2018, 68-69, 44-66.	3.6	230
3	Autosomal-Recessive Mutations in SLC34A1 Encoding Sodium-Phosphate Cotransporter 2A Cause Idiopathic Infantile Hypercalcemia. Journal of the American Society of Nephrology: JASN, 2016, 27, 604-614.	6.1	207
4	Cystinosis: a review. Orphanet Journal of Rare Diseases, 2016, 11, 47.	2.7	188
5	Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters. Cell and Tissue Research, 2010, 339, 449-457.	2.9	167
6	Nephropathic cystinosis: an international consensus document. Nephrology Dialysis Transplantation, 2014, 29, iv87-iv94.	0.7	164
7	OCRL controls trafficking through early endosomes via PtdIns4,5P₂-dependent regulation of endosomal actin. EMBO Journal, 2011, 30, 4970-4985.	7.8	158
8	Cysteamine: an old drug with new potential. Drug Discovery Today, 2013, 18, 785-792.	6.4	156
9	Polyhydramnios, Transient Antenatal Bartterâ€™s Syndrome, andMAGED2Mutations. New England Journal of Medicine, 2016, 374, 1853-1863.	27.0	148
10	Autophagosomeâ€“lysosome fusion triggers a lysosomal response mediated by TLR9 and controlled by OCRL. Nature Cell Biology, 2016, 18, 839-850.	10.3	140
11	Genotypeâ€“phenotype studies in nail-patella syndrome show that LMX1B mutation location is involved in the risk of developing nephropathy. European Journal of Human Genetics, 2005, 13, 935-946.	2.8	129
12	Long-Term Outcome of Biopsy-Proven, Frequently Relapsing Minimal-Change Nephrotic Syndrome in Children. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1593-1600.	4.5	117
13	Renal Phenotype in Lowe Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1430-1436.	4.5	116
14	Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatric Nephrology, 2008, 23, 2013-2020.	1.7	102
15	Cystinosis: practical tools for diagnosis and treatment. Pediatric Nephrology, 2011, 26, 205-215.	1.7	98
16	The pathogenesis of cystinosis: mechanisms beyond cystine accumulation. American Journal of Physiology - Renal Physiology, 2010, 299, F905-F916.	2.7	91
17	Cysteamine restores glutathione redox status in cultured cystinotic proximal tubular epithelial cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 643-651.	3.8	85
18	Novel perspectives for investigating congenital anomalies of the kidney and urinary tract (CAKUT). Nephrology Dialysis Transplantation, 2011, 26, 3843-3851.	0.7	78

#	Article	IF	Citations
19	Time Course of Pathogenic and Adaptation Mechanisms in Cystinotic Mouse Kidneys. Journal of the American Society of Nephrology: JASN, 2014, 25, 1256-1269.	6.1	75
20	Treatment and long-term outcome in primary distal renal tubular acidosis. Nephrology Dialysis Transplantation, 2019, 34, 981-991.	0.7	75
21	Receptor-mediated endocytosis and endosomal acidification is impaired in proximal tubule epithelial cells of Dent disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7014-7019.	7.1	71
22	Bigenic heterozygosity and the development of steroid-resistant focal segmental glomerulosclerosis. Nephrology Dialysis Transplantation, 2008, 23, 3146-3151.	0.7	69
23	Improvement in the Renal Prognosis in Nephropathic Cystinosis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2485-2491.	4.5	68
24	Elevated oxidized glutathione in cystinotic proximal tubular epithelial cells. Biochemical and Biophysical Research Communications, 2005, 337, 610-614.	2.1	66
25	Autophagy in renal diseases. Pediatric Nephrology, 2016, 31, 737-752.	1.7	66
26	Stem Cell Microvesicles Transfer Cystinosin to Human Cystinotic Cells and Reduce Cystine Accumulation In Vitro. PLoS ONE, 2012, 7, e42840.	2.5	63
27	From gut to kidney: Transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. International Journal of Pharmaceutics, 2013, 452, 14-35.	5.2	63
28	Cysteamine Toxicity in Patients with Cystinosis. Journal of Pediatrics, 2011, 159, 1004-1011.	1.8	61
29	Altered status of glutathione and its metabolites in cystinotic cells. Nephrology Dialysis Transplantation, 2005, 20, 1828-1832.	0.7	59
30	Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis. Pediatric Nephrology, 2006, 21, 110-113.	1.7	58
31	The origin of halitosis in cystinotic patients due to cysteamine treatment. Molecular Genetics and Metabolism, 2007, 91, 228-233.	1.1	58
32	Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrologyâ€"Children and Adolescents (SONG-KIDS) consensus workshops. Kidney International, 2020, 98, 553-565.	5.2	58
33	Cystinuria: clinical practice recommendation. Kidney International, 2021, 99, 48-58.	5.2	58
34	Criteria for HNF1B analysis in patients with congenital abnormalities of kidney and urinary tract. Nephrology Dialysis Transplantation, 2015, 30, 835-842.	0.7	57
35	Long-Term Outcome After Cyclophosphamide Treatment in Children With Steroid-Dependent and Frequently Relapsing Minimal Change Nephrotic Syndrome. American Journal of Kidney Diseases, 2007, 49, 592-597.	1.9	54
36	Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatric Nephrology, 2001, 16, 878-884.	1.7	53

#	Article	IF	Citations
37	Renal function in children and adolescents with Duchenne muscular dystrophy. Neuromuscular Disorders, 2015, 25, 381-387.	0.6	53
38	Decreased Intracellular ATP Content and Intact Mitochondrial Energy Generating Capacity in Human Cystinotic Fibroblasts. Pediatric Research, 2006, 59, 287-292.	2.3	52
39	Controversies and research agenda in nephropathic cystinosis: conclusions from a â€œKidney Disease: Improving Global Outcomesâ€•(KDIGO) Controversies Conference. Kidney International, 2016, 89, 1192-1203.	5.2	52
40	APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of Actomyosin. Cell Reports, 2020, 30, 3821-3836.e13.	6.4	50
41	Fertility status in male cystinosis patients treated with cysteamine. Fertility and Sterility, 2010, 93, 1880-1883.	1.0	49
42	Endo-Lysosomal Dysfunction in Human Proximal Tubular Epithelial Cells Deficient for Lysosomal Cystine Transporter Cystinosin. PLoS ONE, 2015, 10, e0120998.	2.5	47
43	Catchâ€“up growth in the first two years of life in Extremely Low Birth Weight (ELBW) infants is associated with lower body fat in young adolescence. PLoS ONE, 2017, 12, e0173349.	2.5	46
44	Urinary Protein Excretion Pattern and Renal Expression of Megalin and Cubilin in Nephropathic Cystinosis. American Journal of Kidney Diseases, 2008, 51, 893-903.	1.9	45
45	Postnatal trends in creatinemia and its covariates in extremely low birth weight (ELBW) neonates. Pediatric Nephrology, 2011, 26, 1843-1849.	1.7	45
46	Human Urine as a Noninvasive Source of Kidney Cells. Stem Cells International, 2015, 2015, 1-7.	2.5	45
47	Altered mTOR signalling in nephropathic cystinosis. Journal of Inherited Metabolic Disease, 2016, 39, 457-464.	3.6	45
48	Immunomodulatory Effects of Chitotriosidase Enzyme. Enzyme Research, 2016, 2016, 1-9.	1.8	44
49	Molecular Basis of Cystinosis: Geographic Distribution, Functional Consequences of Mutations in the <i>CTNS</i> Gene, and Potential for Repair. Nephron, 2019, 141, 133-146.	1.8	44
50	Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group. Nature Reviews Nephrology, 2021, 17, 277-289.	9.6	41
51	Sedoheptulokinase deficiency due to a 57-kb deletion in cystinosis patients causes urinary accumulation of sedoheptulose: elucidation of theCARKLgene. Human Mutation, 2008, 29, 532-536.	2.5	40
52	Genetic Identification of Two Novel Loci Associated with Steroid-Sensitive Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2019, 30, 1375-1384.	6.1	40
53	APOL1 Risk Genotypes Are Associated WithÂEarly Kidney Damage in Children inÂSub-Saharan Africa. Kidney International Reports, 2019, 4, 930-938.	0.8	39
54	Management of bone disease in cystinosis: Statement from an international conference. Journal of Inherited Metabolic Disease, 2019, 42, 1019-1029.	3.6	39

#	Article	IF	Citations
55	Comparison of Cystine Determination in Mixed Leukocytes vs Polymorphonuclear Leukocytes for Diagnosis of Cystinosis and Monitoring of Cysteamine Therapy. Clinical Chemistry, 2004, 50, 1686-1688.	3.2	38
56	Nephropathic cystinosis: an update. Current Opinion in Pediatrics, 2017, 29, 168-178.	2.0	38
57	Amniotic Fluid Derived Stem Cells with a Renal Progenitor Phenotype Inhibit Interstitial Fibrosis in Renal Ischemia and Reperfusion Injury in Rats. PLoS ONE, 2015, 10, e0136145.	2.5	37
58	Creatinine reference values in ELBW infants: impact of quantification by Jaffe or enzymatic method. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 1678-1681.	1.5	36
59	Cystinosis (ctns) zebrafish mutant shows pronephric glomerular and tubular dysfunction. Scientific Reports, 2017, 7, 42583.	3.3	36
60	Analysis of CTNS gene transcripts in nephropathic cystinosis. Pediatric Nephrology, 2010, 25, 1263-1267.	1.7	34
61	Copper Deficiency in Patients with Cystinosis with Cysteamine Toxicity. Journal of Pediatrics, 2013, 163, 754-760.	1.8	34
62	Mutational Spectrum of the CTNS Gene in Egyptian Patients with Nephropathic Cystinosis. JIMD Reports, 2014, 14, 87-97.	1.5	34
63	Renal Precision Medicine in Neonates and Acute Kidney Injury: How to Convert a Cloud of Creatinine Observations to Support Clinical Decisions. Frontiers in Pediatrics, 2020, 8, 366.	1.9	34
64	Role of Tc-99m DMSA scintigraphy in the diagnosis of culture negative pyelonephritis. Pediatric Nephrology, 2001, 16, 503-506.	1.7	33
65	Identification and subcellular localization of a new cystinosin isoform. American Journal of Physiology - Renal Physiology, 2008, 294, F1101-F1108.	2.7	33
66	Homozygosity for aquaporin 7 G264V in three unrelated children with hyperglyceroluria and a mild platelet secretion defect. Genetics in Medicine, 2013, 15, 55-63.	2.4	33
67	Follow-up and treatment of adults with cystinosis in the Netherlands. Nephrology Dialysis Transplantation, 2002, 17, 1766-1770.	0.7	32
68	Urine of Preterm Neonates as a Novel Source of Kidney Progenitor Cells. Journal of the American Society of Nephrology: JASN, 2016, 27, 2762-2770.	6.1	32
69	Cystinosin deficiency causes podocyte damage and loss associated with increased cell motility. Kidney International, 2016, 89, 1037-1048.	5.2	32
70	Genetic Renal Diseases: The Emerging Role of Zebrafish Models. Cells, 2018, 7, 130.	4.1	32
71	NLRP2 Regulates Proinflammatory and Antiapoptotic Responses in Proximal Tubular Epithelial Cells. Frontiers in Cell and Developmental Biology, 2019, 7, 252.	3.7	31
72	The impact of COVID-19 pandemic on the diagnosis and management of inborn errors of metabolism: A global perspective. Molecular Genetics and Metabolism, 2020, 131, 285-288.	1.1	31

#	Article	IF	Citations
73	An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis. Kidney International, 2021, 100, 1112-1123.	5.2	31
74	Detailed studies of growth hormone secretion in cystinosis patients. Pediatric Nephrology, 2012, 27, 2123-2127.	1.7	28
75	The Functional Implications of Common Genetic Variation in CYP3A5 and ABCB1 in Human Proximal Tubule Cells. Molecular Pharmaceutics, 2015, 12, 758-768.	4.6	28
76	Genetic aspects of congenital nephrotic syndrome: a consensus statement from the ERKNetâ€“ESPN inherited glomerulopathy working group. European Journal of Human Genetics, 2020, 28, 1368-1378.	2.8	28
77	Nephrogenic syndrome of inappropriate antidiuresis. Nephrology Dialysis Transplantation, 2010, 25, 2839-2843.	0.7	27
78	Clinical utility gene card for: Cystinosis. European Journal of Human Genetics, 2014, 22, 713-713.	2.8	27
79	Platelet abnormalities in nephrotic syndrome. Pediatric Nephrology, 2016, 31, 1267-1279.	1.7	27
80	Does Extremely Low Birth Weight Predispose to Low-Renin Hypertension?. Hypertension, 2017, 69, 443-449.	2.7	27
81	Vascular Endothelial Growth Factor Up-regulation in Human Amniotic Fluid Stem Cell Enhances Nephroprotection After Ischemia-Reperfusion Injury in the Rat. Critical Care Medicine, 2017, 45, e86-e96.	0.9	27
82	The Molecular Basis of Dutch Infantile Nephropathic Cystinosis. Nephron, 2001, 89, 50-55.	1.8	26
83	Reduced elastogenesis: a clue to the arteriosclerosis and emphysematous changes in Schimke immuno-osseous dysplasia?. Orphanet Journal of Rare Diseases, 2012, 7, 70.	2.7	26
84	Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium. Frontiers in Endocrinology, 2021, 12, 641543.	3.5	26
85	The European Rare Kidney Disease Registry (ERKReg): objectives, design and initial results. Orphanet Journal of Rare Diseases, 2021, 16, 251.	2.7	26
86	Neurocognitive functioning in schoolâ€aged cystinosis patients. Journal of Inherited Metabolic Disease, 2010, 33, 787-793.	3.6	24
87	A new approach to imprinting mutation detection in GNAS by Sequenom EpiTYPER system. Clinica Chimica Acta, 2010, 411, 2033-2039.	1.1	24
88	Cystine Dimethylester Model of Cystinosis: Still Reliable?. Pediatric Research, 2007, 62, 151-155.	2.3	23
89	Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis. Orphanet Journal of Rare Diseases, 2014, 9, 155.	2.7	23
90	3DUS as an alternative to MRI for measuring renal volume in children with autosomal dominant polycystic kidney disease. Pediatric Nephrology, 2018, 33, 827-835.	1.7	23

#	Article	IF	Citations
91	Cysteamineâ€“bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis. EMBO Molecular Medicine, 2021, 13, e13067.	6.9	23
92	Cliniciansâ€™ attitude towards family planning and timing of diagnosis in autosomal dominant polycystic kidney disease. PLoS ONE, 2017, 12, e0185779.	2.5	21
93	Growth hormone therapy influences endothelial function in children with renal failure. Pediatric Nephrology, 2004, 19, 785-789.	1.7	20
94	Facilitators and Barriers of Medication Adherence in Pediatric Liver and Kidney Transplant Recipients: A Mixed-Methods Study. Progress in Transplantation, 2014, 24, 311-321.	0.7	20
95	Clinical Practice: A Proposed Standardized Ophthalmological Assessment for Patients with Cystinosis. Ophthalmology and Therapy, 2017, 6, 93-104.	2.3	20
96	A promising pediatric peritoneal dialysis experience in a resource-limited setting with the support of saving young lives program. Peritoneal Dialysis International, 2020, 40, 504-508.	2.3	20
97	Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate. Molecular Genetics and Metabolism, 2012, 107, 234-236.	1.1	19
98	Serum Shiga toxin 2 values in patients during acute phase of diarrhoeaâ€associated haemolytic uraemic syndrome. Acta Paediatrica, International Journal of Paediatrics, 2015, 104, e564-8.	1.5	19
99	Design and feasibility of â€œPREMATurity as predictor of children's Cardiovascularâ€“renal Healthâ€• (PREMATCH): A pilot study. Blood Pressure, 2015, 24, 275-283.	1.5	19
100	Renal involvement in PMM2-CDG, a mini-review. Molecular Genetics and Metabolism, 2018, 123, 292-296.	1.1	19
101	Allogeneic HSCT transfers wild-type cystinosin to nonhematological epithelial cells in cystinosis: First human report. American Journal of Transplantation, 2018, 18, 2823-2828.	4.7	19
102	Chronic Aichi Virus Infection in a Patient with X-Linked Agammaglobulinemia. Journal of Clinical Immunology, 2018, 38, 748-752.	3.8	18
103	The ANTENATAL multicentre study to predict postnatal renal outcome in fetuses with posterior urethral valves: objectives and design. CKJ: Clinical Kidney Journal, 2020, 13, 371-379.	2.9	18
104	Cell-Based Phenotypic Drug Screening Identifies Luteolin as Candidate Therapeutic for Nephropathic Cystinosis. Journal of the American Society of Nephrology: JASN, 2020, 31, 1522-1537.	6.1	18
105	Chitotriosidase as a Novel Biomarker for Therapeutic Monitoring of Nephropathic Cystinosis. Journal of the American Society of Nephrology: JASN, 2020, 31, 1092-1106.	6.1	18
106	Distal renal tubular acidosis: ERKNet/ESPN clinical practice points. Nephrology Dialysis Transplantation, 2021, 36, 1585-1596.	0.7	18
107	Mitochondrial Complex V Expression and Activity in Cystinotic Fibroblasts. Pediatric Research, 2008, 64, 495-497.	2.3	17
108	Apparent Mineralocorticoid Excess: Time of Manifestation and Complications Despite Treatment. Pediatrics, 2011, 127, e1610-e1614.	2.1	17

#	Article	IF	Citations
109	Characterizing dynamics of serum creatinine and creatinine clearance in extremely low birth weight neonates during the first 6 weeks of life. Pediatric Nephrology, 2021, 36, 649-659.	1.7	17
110	Attitude of Belgian pediatricians toward strategy in acute pyelonephritis. Pediatric Nephrology, 2001, 16, 113-115.	1.7	16
111	Increased Wnt and Notch signaling: a clue to the renal disease in Schimke immuno-osseous dysplasia?. Orphanet Journal of Rare Diseases, 2016, 11, 149.	2.7	16
112	Prevention of relapses with levamisole as adjuvant therapy in children with a first episode of idiopathic nephrotic syndrome: study protocol for a double blind, randomised placebo-controlled trial (the LEARNS study). BMJ Open, 2019, 9, e027011.	1.9	16
113	Molecular Mechanisms and Treatment Options of Nephropathic Cystinosis. Trends in Molecular Medicine, 2021, 27, 673-686.	6.7	16
114	Development of Fanconi syndrome during infancy in a patient with cystinosis. Acta Paediatrica, International Journal of Paediatrics, 2006, 95, 379-380.	1.5	16
115	Distribution of cystinosin-LKG in human tissues. Histochemistry and Cell Biology, 2012, 138, 351-363.	1.7	15
116	Management dilemmas in pediatric nephrology: Cystinosis. Pediatric Nephrology, 2015, 30, 1349-1360.	1.7	15
117	Evidence for Bone and Mineral Metabolism Alterations in Children With Autosomal Dominant Polycystic Kidney Disease. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4210-4217.	3.6	15
118	Extremely Low Birth Weight Predisposes to Impaired Renal Health: A Pooled Analysis. Kidney and Blood Pressure Research, 2019, 44, 897-906.	2.0	15
119	A focus on the association of Apol1 with kidney disease in children. Pediatric Nephrology, 2021, 36, 777-788.	1.7	15
120	Amniotic fluid peptides predict postnatal kidney survival in developmental kidney disease. Kidney International, 2021, 99, 737-749.	5.2	15
121	Creatinaemia at birth is equal to maternal creatinaemia at delivery:does this paradigm still hold?. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 978-980.	1.5	14
122	Population-specific serum creatinine centiles in neonates with posterior urethral valves already predict long-term renal outcome. Journal of Maternal-Fetal and Neonatal Medicine, 2015, 28, 1026-1031.	1.5	14
123	Renal Replacement Therapy in children with severe developmental disability: guiding questions for decision-making. European Journal of Pediatrics, 2018, 177, 1735-1743.	2.7	14
124	The potential of RNA-based therapy for kidney diseases. Pediatric Nephrology, 2023, 38, 327-344.	1.7	14
125	Molecular and functional characterization of urineâ€derived podocytes from patients with Alport syndrome. Journal of Pathology, 2020, 252, 88-100.	4.5	13
126	Neonatal circulatory failure due to acute hypertensive crisis : clinical and echocardiographic clues : cardiovascular topics. Cardiovascular Journal of Africa, 2013, 24, 72-75.	0.4	13

#	Article	IF	Citations
127	No evidence of hearing loss in pseudohypoaldosteronism type 1 patients. Acta Oto-Laryngologica, 2006, 126, 237-239.	0.9	12
128	Pharmacokinetics of cysteamine in a cystinosis patient treated with hemodialysis. Pediatric Nephrology, 2011, 26, 639-640.	1.7	12
129	Cystinosis: a new perspective. Acta Clinica Belgica, 2016, 71, 131-137.	1.2	12
130	Occurrence of atypical HUS associated with influenza B. European Journal of Pediatrics, 2017, 176, 449-454.	2.7	12
131	First Successful Conception Induced by a Male Cystinosis Patient. JIMD Reports, 2017, 38, 1-6.	1.5	12
132	Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. Acta Clinica Belgica, 2018, 73, 80-89.	1.2	12
133	Cystinosis: clinical presentation, pathogenesis and treatment. Pediatric Endocrinology Reviews, 2014, 12 Suppl 1, 176-84.	1.2	12
134	Tacrolimus dose requirements in paediatric renal allograft recipients are characterized by a biphasic course determined by age and bone maturation. British Journal of Clinical Pharmacology, 2017, 83, 863-874.	2.4	11
135	Effect of Storage Conditions on Stability of Ophthalmological Compounded Cysteamine Eye Drops. JIMD Reports, 2017, 42, 47-51.	1.5	11
136	Role of P-Glycoprotein Expression and Function in Cystinotic Renal Proximal Tubular Cells. Pharmaceutics, 2011, 3, 782-792.	4.5	10
137	Ibuprofen exposure in early neonatal life does not affect renal function in young adolescence. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2018, 103, F107-F111.	2.8	10
138	The European Society for Paediatric Nephrology study of pediatric renal care in Europe: comparative analysis 1998â€“2017. Pediatric Nephrology, 2020, 35, 103-111.	1.7	10
139	Urine-Derived Epithelial Cells as Models for Genetic Kidney Diseases. Cells, 2021, 10, 1413.	4.1	10
140	Evaluation of the proximal tubular function in hereditary renal Fanconi syndrome. Nephrology Dialysis Transplantation, 2008, 23, 2719-2722.	0.7	9
141	Pauci-immune crescentic glomerulonephritis complicating SjÃ¶gren's syndrome in a 12-year-old girl. Pediatric Nephrology, 2011, 26, 991-992.	1.7	9
142	Clinical utility gene card for: Dent disease (Dent-1 and Dent-2). European Journal of Human Genetics, 2014, 22, 1338-1338.	2.8	9
143	Measuring glomerular filtration rate using 51Cr-EDTA. Nuclear Medicine Communications, 2014, 35, 1150-1155.	1.1	9
144	Evaluation of carbohydrate-cysteamine thiazolidines as pro-drugs for the treatment of cystinosis. Carbohydrate Research, 2017, 439, 9-15.	2.3	9

#	Article	IF	Citations
145	Fulminant Wilson Disease in Children. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 720-725.	1.8	9
146	Expert guidance on the multidisciplinary management of cystinosis in adolescent and adult patients. CKJ: Clinical Kidney Journal, 2022, 15, 1675-1684.	2.9	9
147	Effective chemical preservation of morphology of urinary erythrocytes. Pediatric Nephrology, 2003, 18, 665-666.	1.7	8
148	Charcotâ€“Marieâ€“Tooth: Are you testing for proteinuria?. European Journal of Paediatric Neurology, 2015, 19, 1-5.	1.6	8
149	Endocrine Complications of Cystinosis. Journal of Pediatrics, 2017, 183, S5-S8.	1.8	8
150	Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature. Acta Clinica Belgica, 2017, 72, 147-155.	1.2	8
151	Liver involvement in kidney disease and vice versa. Pediatric Nephrology, 2018, 33, 957-971.	1.7	8
152	Bortezomib for autoimmune hemolytic anemia after intestinal transplantation. Pediatric Transplantation, 2020, 24, e13700.	1.0	8
153	Therapeutic concentrations of calcineurin inhibitors do not deregulate glutathione redox balance in human renal proximal tubule cells. PLoS ONE, 2021, 16, e0250996.	2.5	8
154	Novel Human Podocyte Cell Model Carrying G2/G2 APOL1 High-Risk Genotype. Cells, 2021, 10, 1914.	4.1	8
155	Necessity of Fractionated Urine Collection for Monitoring Patients with Cystinuria. Clinical Chemistry, 2011, 57, 780-781.	3.2	7
156	Urinary excretion of polyols and sugars in children with chronic kidney disease. Pediatric Nephrology, 2015, 30, 1537-1540.	1.7	7
157	Clinical and genetic factors are associated with kidney complications in African children with sickle cell anaemia. British Journal of Haematology, 2021, , .	2.5	7
158	EUNEFRON, the European Network for the Study of Orphan Nephropathies. Nephrology Dialysis Transplantation, 2009, 24, 2011-2015.	0.7	6
159	FXYD2 and Na,K-ATPase Expression in Isolated Human Proximal Tubular Cells: Disturbed Upregulation on Renal Hypomagnesemia?. Journal of Membrane Biology, 2009, 231, 117-124.	2.1	6
160	Improving the prognosis of nephropathic cystinosis. International Journal of Nephrology and Renovascular Disease, 2014, 7, 297.	1.8	6
161	Pituitary adenylate cyclase-activating polypeptide (PACAP) in zebrafish models of nephrotic syndrome. PLoS ONE, 2017, 12, e0182100.	2.5	6
162	Human and animal fertility studies in cystinosis reveal signs of obstructive azoospermia, an altered bloodâ€testis barrier and a subtherapeutic effect of cysteamine in testis. Journal of Inherited Metabolic Disease, 2021, 44, 1393-1408.	3.6	6

#	Article	IF	Citations
163	An Unusual Presentation of Denys-Drash Syndrome Due to Bigenic Disease. Pediatrics, 2014, 133, e252-e256.	2.1	5
164	Ca2+ signalling in human proximal tubular epithelial cells deficient for cystinosin. Cell Calcium, 2016, 60, 282-287.	2.4	5
165	Enhanced Intrinsic Skin Aging in Nephropathic Cystinosis Assessed by High-Definition Optical Coherence Tomography. Journal of Investigative Dermatology, 2019, 139, 2242-2245.e5.	0.7	5
166	Keratinocytic epidermal nevi associated with localized fibroâ€osseous lesions without hypophosphatemia. Pediatric Dermatology, 2020, 37, 890-895.	0.9	5
167	Retinal and Renal Microvasculature in Relation to Central Hemodynamics in 11â€Yearâ€Old Children Born Preterm or At Term. Journal of the American Heart Association, 2020, 9, e014305.	3.7	5
168	Sickle cell nephropathy: insights into the pediatric population. Pediatric Nephrology, 2022, 37, 1231-1243.	1.7	5
169	Benefits and Toxicity of Disulfiram in Preclinical Models of Nephropathic Cystinosis. Cells, 2021, 10, 3294.	4.1	5
170	Parathyroid hormone and phosphate homeostasis in patients with Bartter and Gitelman syndrome: an international cross-sectional study. Nephrology Dialysis Transplantation, 2022, 37, 2474-2486.	0.7	5
171	The Use of CDME in Cystinosis Research. Neurochemical Research, 2008, 33, 2373-2374.	3.3	4
172	Growth hormone producing prolactinoma in juvenile cystinosis: a simple coincidence?. Pediatric Nephrology, 2008, 23, 307-310.	1.7	4
173	Bone marrow aplasia and graft loss in a pediatric renal transplant patient with polyomavirus nephropathy. Pediatric Nephrology, 2010, 25, 2191-2192.	1.7	4
174	Switch in FGFR3 and -4 Expression Profile During Human Renal Development May Account for Transient Hypercalcemia in Patients With Sotos Syndrome due to 5q35 Microdeletions. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1361-E1367.	3.6	4
175	Neonatal creatinemia trends as biomarker of subsequent cognitive outcome in extremely low birth weight neonates. Early Human Development, 2015, 91, 367-372.	1.8	4
176	A pediatric gateway initiative for glomerular disease: introducing PIONEER. Kidney International, 2021, 99, 515-518.	5.2	4
177	Glomerular developmental delay and proteinuria in the preterm neonatal rabbit. PLoS ONE, 2020, 15, e0241384.	2.5	4
178	Renal and Extra Renal Manifestations in Adult Zebrafish Model of Cystinosis. International Journal of Molecular Sciences, 2021, 22, 9398.	4.1	3
179	Biallelic variants in MESD, which encodes a WNT-signaling-related protein, in four new families with recessively inherited osteogenesis imperfecta. Human Genetics and Genomics Advances, 2021, 2, 100051.	1.7	3
180	Pregnancy in cystinosis patients with chronic kidney disease: A European case series. Journal of Inherited Metabolic Disease, 2022, 45, 963-968.	3.6	3

#	Article	IF	Citations
181	Studying nonobstructive azoospermia in cystinosis: histologicÂexamination of testes andÂepididymis and sperm analysis inÂa Ctnsâ¯/â¯ mouse model. Fertility and Sterility, 2012, 98, 162-165.	1.0	2
182	Clinical utility gene card for: Lowe syndrome. European Journal of Human Genetics, 2015, 23, 889-889.	2.8	2
183	The Case | Hypercalcemia in a child with chronic kidney disease. Kidney International, 2016, 90, 233-234.	5.2	2
184	Analysis of renal blood flow and renal volume in normal fetuses and in fetuses with a solitary functioning kidney. Prenatal Diagnosis, 2017, 37, 1213-1218.	2.3	2
185	Ophthalmic Outcome in a Belgian Cohort of Cystinosis Patients Treated with a Compounded Preparation of Cysteamine Eye Drops: Retrospective Analysis. Ophthalmology and Therapy, 2019, 8, 623-633.	2.3	2
186	A Human Proximal Tubular Epithelial Cell Model to Explore a Knowledge Gap on Neonatal Drug Disposition. Current Pharmaceutical Design, 2018, 23, 5911-5918.	1.9	2
187	Urine-Derived Kidney Progenitor Cells in Cystinosis. Cells, 2022, 11, 1245.	4.1	2
188	Biomarkers in Nephropathic Cystinosis: Current and Future Perspectives. Cells, 2022, 11, 1839.	4.1	2
189	Simplified screening criteria for HNF1B analysis. Kidney International, 2015, 87, 1258-1259.	5.2	1
190	Preserving oral history: 50 years of paediatric nephrology in Europe. Archives of Disease in Childhood, 2018, 103, archdischild-2018-315308.	1.9	1
191	51Cr-EDTA plasma clearance in children. Medicine (United States), 2022, 101, e28608.	1.0	1
192	A Patient with neonatal cholestasis. Medycyna Wieku Rozwojowego, 2021, 24, 31-33.	0.2	1
193	Reply to the letter from J.H.H. Ehrich. Pediatric Nephrology, 2006, 21, 1214-1214.	1.7	0
194	Management of nephropathic cystinosis. Expert Opinion on Orphan Drugs, 2013, 1, 1031-1039.	0.8	0
195	Simplified Thresholds for Pediatric (Pre)hypertension. Hypertension, 2017, 69, 587-588.	2.7	0
196	Rethinking peritubular capillary basement membrane multilayering in renal transplant pathology: a case report. Pediatric Nephrology, 2017, 32, 697-701.	1.7	0
197	SP781THE EFFECT OF IN VITRO TACROLIMUS EXPOSURE AND PHARMACOGENETIC VARIATION ON MULTILEVEL CYP3A5, ABCB1 EXPRESSION AND CTGF PRODUCTION IN HUMAN PROXIMAL TUBULE CELLS. Nephrology Dialysis Transplantation, 2017, 32, iii407-iii407.	0.7	0
198	FP755EUROPEAN SOCIETY OF PAEDIATRIC NEPHROLOGY (ESPN) STUDY OF PAEDIATRIC RENAL CARE IN EUROPE: COMPARATIVE ANALYSIS 1998 - 2017. Nephrology Dialysis Transplantation, 2018, 33, i301-i301.	0.7	0

#	Article	IF	Citations
199	Heterogeneous Recommendations for School Attendance in Children With Chronic Kidney Diseases During the COVID-19 Pandemic in Europe. Frontiers in Pediatrics, 2021, 9, 646595.	1.9	0
200	The choice between deceased and living donor kidney transplantation in children and adolescents: a multicentric cross-sectional study. Acta Clinica Belgica, 2021, , 1-7.	1.2	0
201	A Personal History of Cystinosis by Dr. Jerry Schneider. Cells, 2022, 11, 945.	4.1	0